Carlson Robert W
Division of Medical Oncology, Stanford Hospital and Clinics, Stanford, California, USA.
J Natl Compr Canc Netw. 2003 Jan;1 Suppl 1:S61-3.
The 2002 NCCN Breast Cancer Clinical Practice Guidelines in Oncology represent the 7th annual update produced by a multidisciplinary panel of breast cancer experts from the NCCN member institutions. The Breast Cancer Panel uses an objective, evidence-based method when high-level evidence from clinical trials exists. In clinical situations in which high-level evidence is lacking, recommendations are generated through a multidisciplinary consensus development process. The NCCN institutions also review the complete guideline on an annual basis. In this update, several of the modifications in the 2002 Breast Cancer Guidelines are highlighted, including the use of aromatase inhibitors and leuteinizing hormone-releasing hormone agonists plus tamoxifen in the first-line therapy of metastatic breast cancer and the use of anastrozole in the adjuvant setting. The new guidelines for axillary lymph node staging are reported on in a companion article in this issue.
2002年美国国立综合癌症网络（NCCN）《肿瘤学临床实践指南：乳腺癌》是由NCCN成员机构的乳腺癌专家多学科小组进行的第7次年度更新。当有来自临床试验的高级别证据时，乳腺癌小组采用客观的、基于证据的方法。在缺乏高级别证据的临床情况下，通过多学科共识制定过程产生建议。NCCN机构每年也会对完整的指南进行审查。在本次更新中，重点介绍了2002年乳腺癌指南中的几项修改内容，包括在转移性乳腺癌一线治疗中使用芳香化酶抑制剂和促黄体生成素释放激素激动剂加他莫昔芬，以及在辅助治疗中使用阿那曲唑。本期的一篇配套文章报道了腋窝淋巴结分期的新指南。
